Verge Genomics is redefining drug discovery by harnessing artificial intelligence and proprietary human genomic data to tackle the high rates of clinical trial failures, which are a major factor driving up drug costs. With one of the largest collections of patient molecular and clinical data sourced directly from human tissue, Verge has already brought two drugs to clinical trial and established significant partnerships with leading pharmaceutical companies like Eli Lilly and AstraZeneca.
